Mazdutide Injection | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Company: Innovent Biologics (Suzhou) Co., Ltd.
Medicine type: Chemical medicine
Therapeutic area: Endocrinology & metabolism
Indications recorded in the public source: (1) Long-term weight management, alongside dietary control and increased physical activity, in adults with an initial BMI of at least 28 kg/m2 (obesity), or at least 24 kg/m2 (overweight) with at least one weight-related comorbidity, such as hyperglycemia, hypertension, dyslipidemia, fatty liver or obstructive sleep apnea syndrome. (2) Glycemic control in adults with type 2 diabetes: as monotherapy when diet and exercise alone do not provide adequate control; or as combination therapy when control remains inadequate with metformin and/or a sulfonylurea, or metformin and/or a sodium-glucose cotransporter 2 inhibitor (SGLT2 inhibitor), alongside diet and exercise.
Indication source and scope: Source date(s): 2026-05-06. An approval or revision date is blank or a placeholder; the exact revision date is not confirmed.
Prescribing-information limitations: Complete official prescribing information obtained. Mainland China label.
China availability status: Historical Chinese approval verified; current continuous market availability has not been checked for every product.
Overseas status: Market-by-market verification pending.
Insurance classification: Not matched in the 2025 national list; manual review pending
Insurance edition: 2025 edition; effective 1 January 2026
Insurance verification notes: No match in the extracted directory is not proof of exclusion. Compound formulations still require manual review.

Sources

Open the interactive record, public price references and discussions